YAKAWLANG, BAMIYAN PROVINCE, AFGHANISTAN - NOVEMBER 16, 2003. The MSf team prepare to leave the compound in Yakawlang to drive to the Dagah clinic, an hour drive away. MSf has been operating in Afghanistan for over 20 years. The main challenge to provide healthcare in the remote part of the country is isolation and security.
Browse the latest stories and reports on MSF from various media outlets.
Doctors Without Borders/Médecins Sans Frontières (MSF) nurse and researcher, Chenai Mathabire, received the International Aids Society 2017 TB/HIV Research Prize for research on a rapid tuberculosis (TB) test. View External Media.
Following the International AIDS conference, UNAIDS released a report that indicates more than half of the 36.7 million people with HIV have access to treatment for the first time. Despite this encouraging statistic, both HIV and AIDS death rates are increasing in Central Asia and Eastern Europe. NPR spoke with Doctors Without Borders/Médecins Sans Frontières (MSF) HIV and TB policy adviser, Sharonann Lynch, about the most recent HIV/AIDS trends.
A House subcommittee held a hearing on international trade disputes with India. Most of the event was devoted to U.S. drug company Pfizer's complaints about Indian policies that have fostered the country's billion-dollar generics industry.
South Africa has made major progress in the fight against AIDS since 2001, when MSF was the only organization providing antiretroviral treatment in the country. "Adherence clubs" piloted by MSF now make treatment more accessible than ever.
Novartis AG goes to India's Supreme Court on Wednesday to seek patent protection for its blockbuster cancer drug Glivec in a case that could deliver far-reaching ramifications for multinational pharmaceutical companies operating in India.... Novartis's critics, including Médecins Sans Frontières [Doctors Without Borders], say that if the company prevails, it could set a legal precedent that allows pharmaceutical giants to patent a range of drugs in India that are now available from generic producers, including HIV medicines. That would demolish a thriving low-cost industry and lead to higher prices, not just in India, they say, but elsewhere in the developing world where India is a major exporter of drugs.